Photosensitizers for Photodynamic Therapy of Brain Cancers-A Review.
Dorota Bartusik-AebisherPaweł WoźnickiKlaudia DynarowiczDavid AebisherPublished in: Brain sciences (2023)
On average, there are about 300,000 new cases of brain cancer each year. Studies have shown that brain and central nervous system tumors are among the top ten causes of death. Due to the extent of this problem and the percentage of patients suffering from brain tumors, innovative therapeutic treatment methods are constantly being sought. One such innovative therapeutic method is photodynamic therapy (PDT). Photodynamic therapy is an alternative and unique technique widely used in dermatology and other fields of medicine for the treatment of oncological and nononcological lesions. Photodynamic therapy consists of the destruction of cancer cells and inducing inflammatory changes by using laser light of a specific wavelength in combination with the application of a photosensitizer. The most commonly used photosensitizers include 5-aminolevulinic acid for the enzymatic generation of protoporphyrin IX, Temoporfin-THPC, Photofrin, Hypericin and Talaporfin. This paper reviews the photosensitizers commonly used in photodynamic therapy for brain tumors. An overview of all three generations of photosensitizers is presented. Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- white matter
- resting state
- prostate cancer
- systematic review
- end stage renal disease
- randomized controlled trial
- ejection fraction
- patients undergoing
- young adults
- functional connectivity
- papillary thyroid
- patient reported outcomes
- minimally invasive
- cerebral ischemia
- lymph node metastasis
- blood brain barrier
- robot assisted
- smoking cessation
- case control